IP Library › Granted Patent US 12,378,231

Granted Patent B2

US 12,378,231 · App. 18/440,166 · Granted Aug 5, 2025

Small molecules as monoacylglycerol lipase (MAGL) inhibitors, compositions and use thereof

Inventors: Safwat Mohamed Rabea (Richmond, CA); David Earl Bogucki (Surrey, CA); Kaiji Hu (Burnaby, CA)

Assignee: APOGEE PHARMACEUTICALS, INC.

C07D405/14 A61K31/4192 A61K31/454 A61K31/496 A61K31/551 A61K45/06 C07D401/12 C07D471/04 C07D491/056

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 12,378,231
App. No.: 18/440,166
Granted: Aug 5, 2025
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

Disclosed are compounds of Formula I that are useful as Monoacylglycerol lipase (MAGL) inhibitors These compounds may be used in pharmaceutical compositions, formulations, and methods for the treatment of disease states, disorders, and conditions benefited by the inhibition or modulation of MAGL activity, such as, but are not limited to, anxiety and mood disorder, metabolic disorder, a neurodegenerative disorder, mental disorder, brain disorder, pain, inflammatory disorder, cancer, Alzheimer's disease, movement disorders, epilepsy or stroke.

Claims (146)

1. A compound having the Formula I:

a prodrug thereof, or a pharmaceutically acceptable salt thereof,

wherein:

a. X is C, CH, or N;

b. V is O, N (CH 3 ), or none, wherein when V is none, X is directly attached to Y by single or double bond;

C. Y is C, CH, or N;

d. Z is C, CH, or N;

e. W is O or S;

f. M is O, N, or none, wherein when M is none, C═W is directly attached to R 3 ;

g. B is C 4-10 heterocycloalkyl, C 6-12 fused heterocycloalkyl, C 6-12 spirocycloalkyl, azetidinyl, azepanyl, piperazinyl, piperidinyl, diazepanyl, 2-azaspiro[3.3]heptane, 2,5-diazabicyclo[2.2.1]heptane, 8-azabicyclo[3.2.1]octane, 2,6-diazaspiro[3.4]octane, 2,7-diazaspiro[3.5]nonane, 2,7-diazaspiro[4.4]nonane, or 3,9-diazaspiro[5.5]undecane, wherein:

(i) when B is azetidinyl, then Y is CH, and Z is N:

(ii) when B is piperazinyl, then Y is N and Z is N:

(iii) when B is piperidinyl, then Y is CH and Z is N:

(iv) when B is piperid-4,4-diyl, then Y is C and Z is N:

(v) when B is azepanyl, then Y is CH and Z is N:

(vi) when B is diazepanyl, then Y is N and Z is N:

(vii) when B is 2-azaspiro[3.3]heptane, then Y is CH and Z is N:

(viii) when B is 2,6-diazaspiro[3.3]heptane, then Y is N and Z is N:

(ix) when B is 2,5-diazabicyclo[2.2.1]heptane, Y is N and Z is N:

(x) when B is 8-azabicyclo[3.2.1]octane, then Y is N and Z is N:

(xi) when B is 2,6-diazaspiro[3.4]octane, then Y is N and Z is N:

(xii) when B is 2,7-diazaspiro[3.5]nonane, then Y is N and Z is N:

(xiii) when B is 2,7-diazaspiro[4.4]nonane, then Y is N and Z is N:

(xiv) when B is 3,9-diazaspiro[5.5]undecane, then Y is N and Z is N:

h. R 1 and R 2 are each independently aryl, heteroaryl, heterocyclyl, phenyl, pyridyl, benzo-1,3-dioxanyl, benzo-1,4-dioxanyl, benzofuranyl, dihydrobenzofuranyl, benzopyrazolyl, or quinolinyl, wherein each group may be unsubstituted, monosubstituted or disubstituted with an R 5 group; wherein R 5 may be one of the following moieties: alkyl, alkoxy, alkenoxy, halogen, cyano, or pyrazolyl; and

i. R 3 is C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, C 4 -C 8 heterocycloalkyl, aryl, heteroaryl, piperidinyl, piperazinyl, morpholinyl, phenyl, pyridinyl, imidazolyl, pyrazolyl, benzopyrazolyl, triazolyl, benzotriazolyl, pyridotriazolyl, or indanyl, and

R 3 may be unsubstituted or substituted with a R 4 group; wherein R 4 may be one of the following moieties: F, Cl, Br, CF 3 , NO 2 , CN, O, OCH 3 , OCF 3 , C 1 -C 6 alkyl, C 1 -C 6 alkyloxy, C 6 H 5 , OC 6 H 5 , or C(O)OCH 3 , or

j. wherein M and R 3 together form a leaving group;

wherein at least one of R 1 and R 2 is a benzo-1,3-dioxanyl.

2. The compound of claim 1 , having Formula II

a prodrug thereof, or a pharmaceutically acceptable salt thereof.

3. The compound of claim 1 , wherein:

R 1 is benzo-1,3-dioxanyl; and

R 2 is aryl, heteroaryl, phenyl, pyridyl, benzo-1,4-dioxanyl, benzofuranyl, dihydrobenzofuranyl, benzopyrazolyl, or quinolinyl, wherein R 2 may be unsubstituted, monosubstituted, or disubstituted with an R 5 group; wherein R 5 may be one of the following moieties: alkyl, alkoxy, alkenoxy, halogen, cyano, or pyrazolyl.

4. The compound of claim 1 , wherein R 1 is benzo-1,3-dioxanyl and R 2 is pyridyl, having the Formula III:

a prodrug thereof, or a pharmaceutically acceptable salt thereof.

5. The compound of claim 1 , wherein X is nitrogen, having Formula IV

a prodrug thereof, or a pharmaceutically acceptable salt thereof.

6. The compound of claim 1 , wherein X is carbon.

7. The compound of claim 1 , wherein X and Y are carbon, V is none, and X is directly attached to Y by double bond, having Formula V

a prodrug thereof, or a pharmaceutically acceptable salt thereof.

8. The compound of claim 1 , wherein Z is nitrogen.

9. The compound of claim 1 , wherein B is piperazinyl or piperidinyl.

10. The compound of claim 1 , wherein W is O.

11. The compound of claim 1 , wherein W is S.

12. The compound of claim 1 , wherein M is O.

13. The compound of claim 1 , wherein M is N.

14. The compound of claim 1 , wherein Vis O.

15. The compound of claim 1 , wherein

R 3 may be C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, C 4 -C 8 heterocycloalkyl, aryl, heteroaryl, piperidinyl, piperazinyl, morpholinyl, phenyl, pyridinyl, imidazolyl, pyrazolyl, benzopyrazolyl, triazolyl, benzotriazolyl, pyridotriazolyl, or indanyl;

wherein R 3 may be unsubstituted or substituted with an R 4 group; wherein R 4 may be one of the following moieties: F, Cl, Br, CF 3 , NO 2 , CN, O, OCH 3 , OCF 3 , C 1 -C 6 alkyl, C 1 -C 6 alkyloxy, C 6 H 5 , OC 6 H 5 , or C(O)OCH 3 .

16. The compound of claim 1 , wherein the compound is

(4-(bis(4H-benzo[d][1,3]dioxin-6-yl)methyl)piperazin-1-yl)(1H-pyrazol-1-yl)methanone,

(4-(bis(4H-benzo[d][1,3]dioxin-6-yl)methyl)piperazin-1-yl)(3-chloro-1H-1,2,4-triazol-1-yl)methanone,

1,1,1,3,3,3-hexafluoropropan-2-yl 4-(bis(4H-benzo[d][1,3]dioxin-6-yl)methyl)piperazine-1-carboxylate,

4-nitrophenyl 4-(bis(4H-benzo[d][1,3]dioxin-6-yl)methyl)piperazine-1-carboxylate,

4-fluorophenyl 4-(bis(4H-benzo[d][1,3]dioxin-6-yl)methyl)piperazine-1-carboxylate,

2,5-dioxopyrrolidin-1-yl 4-(bis(4H-benzo[d][1,3]dioxin-6-yl)methyl)piperazine-1-carboxylate,

4-phenoxyphenyl 4-(bis(4H-benzo[d][1,3]dioxin-6-yl)methyl)piperazine-1-carboxylate,

(1H-benzo[d][1,2,3]triazol-1-yl)(4-(bis(4H-benzo[d][1,3]dioxin-6-yl)methyl)piperazin-1-yl)methanone,

(4-(bis(4H-benzo[d][1,3]dioxin-6-yl)methyl)piperazin-1-yl)(1H-imidazol-1-yl)methanone,

(4-(bis(4H-benzo[d][1,3]dioxin-6-yl)methyl)piperazin-1-yl)(1H-1,2,4-triazol-1-yl)methanone,

4-(bis(4H-benzo[d][1,3]dioxin-6-yl)methyl)-N-ethyl-N-isopropylpiperazine-1-carboxamide,

2,3-dihydro-1H-inden-5-yl 4-(bis(4H-benzo[d][1,3]dioxin-6-yl)methyl)piperazine-1-carboxylate,

2,4-dinitrophenyl 4-(bis(4H-benzo[d][1,3]dioxin-6-yl)methyl)piperazine-1-carboxylate,

4-methoxyphenyl 4-(bis(4H-benzo[d][1,3]dioxin-6-yl)methyl)piperazine carboxylate,

pentan-3-yl 4-(bis(4H-benzo[d][1,3]dioxin-6-yl)methyl)piperazine-1-carboxylate,

cyclohexyl 4-(bis(4H-benzo[d][1,3]dioxin-6-yl)methyl)piperazine-1-carboxylate,

(4-(bis(4H-benzo[d][1,3]dioxin-6-yl)methyl)piperazin-1-yl)(piperidin-1-yl)methanone,

4-(bis(4H-benzo[d][1,3]dioxin-6-yl)methyl)-N,N-diethylpiperazine-1-carboxamide,

2-fluoro-4-nitrophenyl 4-(bis(4H-benzo[d][1,3]dioxin-6-yl)methyl)piperazine-1-carboxylate,

pyridin-2-yl 4-(bis(4H-benzo[d][1,3]dioxin-6-yl)methyl)piperazine-1-carboxylate,

(4-(bis(4H-benzo[d][1,3]dioxin-6-yl)methyl)piperazin-1-yl)(1H-1,2,4-triazol-1-yl) methanethione,

6-(trifluoromethyl)-1H-benzo[d][1,2,3]triazol-1-yl 4-(bis(4H-benzo[d][1,3]dioxin-6-yl)methyl)piperazine-1-carboxylate,

3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl 4-(bis(4H-benzo[d][1,3]dioxin-6-yl)methyl)piperazine-1-carboxylate,

1-(4-(bis(4H-benzo[d][1,3]dioxin-6-yl)methyl)piperazine-1-carbonyl)-1H-pyrazole-4-carbonitrile,

4-(bis(4H-benzo[d][1,3]dioxin-6-yl)methyl)piperazin-1-yl)(4-phenyl-1H-1,2,3-triazol-1-yl)methanone,

(4-(bis(4H-benzo[d][1,3]dioxin-6-yl)methyl)piperazin-1-yl)(4-phenyl-2H-1,2,3-triazol-2-yl)methanone,

1H-benzo[d][1,2,3]triazol-1-yl 4-(bis(4H-benzo[d][1,3]dioxin-6-yl)methyl)piperazine-1-carboxylate,

(4-(bis(4H-benzo[d][1,3]dioxin-6-yl)methyl)piperazin-1-yl)(3-methyl-1H-1,2,4-triazol-1-yl)methanone,

pentaflurophenyl 4-(bis(4H-benzo[d][1,3]dioxin-6-yl)methyl)piperazine-1-carboxylate,

propan-2-one O-(4-(bis(4H-benzo[d][1,3]dioxin-6-yl)methyl)piperazine-1-carbonyl) oxime,

4-(bis(4H-benzo[d][1,3]dioxin-6-yl)methyl)piperazin-1-yl)(1H-1,2,3-triazol-1-yl)methanone,

(4-(bis(4H-benzo[d][1,3]dioxin-6-yl)methyl)piperazin-1-yl)(2H-1,2,3-triazol-2-yl)methanone,

(3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)(4-(bis(4H-benzo[d][1,3]dioxin-6-yl)methyl)piperazin-1-yl)methanone,

(1H-[1,2,3]triazolo[4,5-b]pyridin-1-yl)(4-(bis(4H-benzo[d][1,3]dioxin-6-yl)methyl)piperazin-1-yl)methanone,

4-(bis(4H-benzo[d][1,3]dioxin-6-yl)methyl)piperazin-1-yl)(5-chloro-1H-benzo[d][1,2,3]triazol-1-yl)methanone,

(4-(bis(4H-benzo[d][1,3]dioxin-6-yl)methyl)piperazin-1-yl)(6-chloro-1H-benzo[d][1,2,3]triazol-1-yl)methanone,

4-(bis(4H-benzo[d][1,3]dioxin-6-yl)methyl)piperazin-1-yl)(5-methyl-1H-benzo[d][1,2,3]triazol-1-yl)methanone,

(4-(bis(4H-benzo[d][1,3]dioxin-6-yl)methyl)piperazin-1-yl)(6-methyl-1H-benzo[d][1,2,3]triazol-1-yl)methanone,

(4-(bis(4H-benzo[d][1,3]dioxin-6-yl)methyl)piperazin-1-yl)(1H-indazol-1-yl)methanone,

1-(4-(bis(4H-benzo[d][1,3]dioxin-6-yl)methyl)piperazine-1-carbonyl)-1H-1,2,4-triazole-3-carbonitrile,

(4-(bis(4H-benzo[d][1,3]dioxin-6-yl)methyl)piperazin-1-yl)(6-bromo-1H-benzo[d][1,2,3]triazol-1-yl)methanone,

(4-(bis(4H-benzo[d][1,3]dioxin-6-yl)methyl)piperazin-1-yl)(5-bromo-1H-benzo[d][1,2,3]triazol-1-yl)methanone,

(4-(bis(4H-benzo[d][1,3]dioxin-6-yl)methyl)piperazin-1-yl)(6-fluoro-1H-benzo[d][1,2,3]triazol-1-yl)methanone,

(4-(bis(4H-benzo[d][1,3]dioxin-6-yl)methyl)piperazin-1-yl)(5-fluoro-1H-benzo[d][1,2,3]triazol-1-yl)methanone,

methyl 1-(4-(bis(4H-benzo[d][1,3]dioxin-6-yl)methyl)piperazine-1-carbonyl)-1H-benzo[d][1,2,3]triazole-5-carboxylate,

methyl 1-(4-(bis(4H-benzo[d][1,3]dioxin-6-yl)methyl)piperazine-1-carbonyl)-1H-benzo[d][1,2,3]triazole-6-carboxylate,

(4-(bis(4H-benzo[d][1,3]dioxin-6-yl)methyl)piperazin-1-yl)(4-chloro-6-(trifluoromethyl)-1H-benzo[d][1,2,3]triazol-1-yl)methanone,

4-(bis(4H-benzo[d][1,3]dioxin-6-yl)methyl)-N-(pyridin-3-yl) piperazine-1-carboxamide,

(4-(bis(4H-benzo[d][1,3]dioxin-6-yl)methyl)piperazin-1-yl)(6-(trifluoromethyl)-1H-benzo[d][1,2,3]triazol-1-yl)methanone,

(4-(bis(4H-benzo[d][1,3]dioxin-6-yl)methyl)piperazin-1-yl)(5-(trifluoromethyl)-1H-benzo[d][1,2,3]triazol-1-yl)methanone,

(4-(bis(4H-benzo[d][1,3]dioxin-6-yl)methyl)piperazin-1-yl)(6,7-dihydro-1H-[1,4]dioxino[2′,3′:4,5]benzo[1,2-d][1,2,3]triazol-1-yl)methanone,

(3H-[1,2,3]triazolo[4,5-c]pyridin-3-yl)(4-(bis(4H-benzo[d][1,3]dioxin-6-yl)methyl)piperazin-1-yl)methanone,

(1H-[1,2,3]triazolo[4,5-c]pyridin-1-yl)(4-(bis(4H-benzo[d][1,3]dioxin-6-yl)methyl)piperazin-1-yl)methanone,

1-(4-(bis(4H-benzo[d][1,3]dioxin-6-yl)methyl)piperazine-1-carbonyl)-1H-benzo[d][1,2,3]triazole-6-carbonitrile,

1-(4-(bis(4H-benzo[d][1,3]dioxin-6-yl)methyl)piperazine-1-carbonyl)-1H-benzo[d][1,2,3]triazole-5-carbonitrile,

2-(4-(bis(4H-benzo[d][1,3]dioxin-6-yl)methyl)piperazine-1-carbonyl)-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one,

1-(4-(bis(4H-benzo[d][1,3]dioxin-6-yl)methyl)-1,4-diazepane-1-carbonyl)-1H-benzo[d][1,2,3]triazole-6-carbonitrile,

(1H-benzo[d][1,2,3]triazol-1-yl)(1-(bis(4H-benzo[d][1,3]dioxin-6-yl)methyl) piperidin-4-yl)methanone,

1,1,1,3,3,3-hexafluoropropan-2-yl 1-(bis(4H-benzo[d][1,3]dioxin-6-yl)methyl) piperidine-4-carboxylate,

pentafluorophenyl 1-(bis(4H-benzo[d][1,3]dioxin-6-yl)methyl) piperidine-4-carboxylate,

1-(4-(bis(4H-benzo[d][1,3]dioxin-6-yl) methoxy) piperidine-1-carbonyl)-1H-benzo[d][1,2,3]triazole-6-carbonitrile,

1-(4-(bis(4H-benzo[d][1,3]dioxin-6-yl) methoxy) piperidine-1-carbonyl)-1H-benzo[d][1,2,3]triazole-5-carbonitrile,

1-(3-(bis(4H-benzo[d][1,3]dioxin-6-yl) methoxy) azetidine-1-carbonyl)-1H-benzo[d][1,2,3]triazole-6-carbonitrile,

1-(3-(bis(4H-benzo[d][1,3]dioxin-6-yl) methoxy) azetidine-1-carbonyl)-1H-benzo[d][1,2,3]triazole-5-carbonitrile,

1-(6-(bis(4H-benzo[d][1,3]dioxin-6-yl) methoxy)-2-azaspiro[3.3]heptane-2-carbonyl)-1H-benzo[d][1,2,3]triazole-6-carbonitrile,

1-(6-(bis(4H-benzo[d][1,3]dioxin-6-yl) methoxy)-2-azaspiro[3.3]heptane-2-carbonyl)-1H-benzo[d][1,2,3]triazole-5-carbonitrile,

1-((15,4S)-5-(bis(4H-benzo[d][1,3]dioxin-6-yl)methyl)-2,5-diazabicyclo[2.2.1]heptane-2-carbonyl)-1H-benzo[d][1,2,3]triazole-6-carbonitrile,

1-((15,45)-5-(bis(4H-benzo[d][1,3]dioxin-6-yl)methyl)-2,5-diazabicyclo[2.2.1]heptane-2-carbonyl)-1H-benzo[d][1,2,3]triazole-5-carbonitrile,

1-(9-(bis(4H-benzo[d][1,3]dioxin-6-yl)methyl)-3,9-diazaspiro[5.5]undecane-3-carbonyl)-1H-1,2,4-triazole-3-carbonitrile,

1-(6-(bis(4H-benzo[d][1,3]dioxin-6-yl)methyl)-2,6-diazaspiro[3.3]heptane-2-carbonyl)-1H-1,2,4-triazole-3-carbonitrile,

meso-1-(5-(bis(4H-benzo[d][1,3]dioxin-6-yl)methyl) octahydropyrrolo[3,4-c]pyrrole-2-carbonyl)-1H-1,2,4-triazole-3-carbonitrile,

1-(7-(bis(4H-benzo[d][1,3]dioxin-6-yl)methyl)-2,7-diazaspiro[3.5]nonane-2-carbonyl)-1H-1,2,4-triazole-3-carbonitrile,

1-(2-(bis(4H-benzo[d][1,3]dioxin-6-yl)methyl)-2,7-diazaspiro[3.5]nonane-7-carbonyl)-1H-1,2,4-triazole-3-carbonitrile,

1-(6-(bis(4H-benzo[d][1,3]dioxin-6-yl)methyl)-2,6-diazaspiro[3.4]octane-2-carbonyl)-1H-1,2,4-triazole-3-carbonitrile,

1-(7-(bis(4H-benzo[d][1,3]dioxin-6-yl)methyl)-2, 7-diazaspiro[4.4]nonane-2-carbonyl)-1H-1,2,4-triazole-3-carbonitrile,

1-(4-((bis(4H-benzo[d][1,3]dioxin-6-yl)methyl)(methyl)amino) piperidine-1-carbonyl)-1H-benzo[d][1,2,3]triazole-6-carbonitrile,

1-(4-((bis(4H-benzo[d][1,3]dioxin-6-yl)methyl)(methyl)amino) piperidine-1-carbonyl)-1H-benzo[d][1,2,3]triazole-5-carbonitrile,

1-(4-(bis(4H-benzo[d][1,3]dioxin-6-yl)methyl) piperidine-1-carbonyl)-1H-1,2,4-triazole-3-carbonitrile,

1-(3-(bis(4H-benzo[d][1,3]dioxin-6-yl)methyl)-8-azabicyclo[3.2.1]octane-8-carbonyl)-1H-1,2,4-triazole-3-carbonitrile,

1-(4-(bis(4H-benzo[d][1,3]dioxin-6-yl)methyl) azepane-1-carbonyl)-1H-1,2,4-triazole-3-carbonitrile,

1-(5-(bis(4H-benzo[d][1,3]dioxin-6-yl)methyl) octahydrocyclopenta[c]pyrrole-2-carbonyl)-1H-1,2,4-triazole-3-carbonitrile, or

1-(6-(bis(4H-benzo[d][1,3]dioxin-6-yl)methyl)-2-azaspiro[3.3]heptane-2-carbonyl)-1H-1,2,4-triazole-3-carbonitrile.

17. A pharmaceutical composition comprising at least one compound of claim 1 and optionally one or more pharmaceutically acceptable excipients or adjuvants.

18. The pharmaceutical composition of claim 17 , comprising an effective amount of the compound, wherein the effective amount is between about 0.0001 to about 1,000 mg.

19. The pharmaceutical composition of claim 17 , further comprising one or more additional therapeutic agent.

20. The pharmaceutical composition of claim 19 , wherein the one or more additional therapeutic agent is selected from the group consisting of: FAAH inhibitors; CB1 cannabinoid receptor agonists; CB2 cannabinoid receptor agonists; phytocannabinoids; non-steroidal anti-inflammatory drugs (NSAIDs); cyclooxygenase-II (COX-II) inhibitors; anti-anxiety agents; antidepressants; antiepileptic drugs; anti-Alzheimer's agents; antipsychotic drugs; antihemorrhagic agents; benzodiazepines; acetylcholinesterase inhibitors; alpha-adrenoreceptor antagonists; alpha-adrenergic receptor agonists; β-blockers; angiotensin-converting enzymes inhibitors (ACEI); serotonin (5-HT) reuptake inhibitors; serotonin and noradrenaline reuptake inhibitors (SNRIs); serotonin 1A (5-HT1A) agonists or antagonists; antibody medicament; antirheumatic drug; therapeutic monoclonal antibodies; and anticancer medications.

21. The pharmaceutical composition of claim 17 formulated for oral, parenteral, and/or transmucosal administration.

22. A method of inhibiting or modulating an endocannabinoid hydrolase, comprising contacting the endocannabinoid hydrolase with the compound of claim 1 .

23. The method of claim 22 , wherein the endocannabinoid hydrolase is a serine hydrolase enzyme.

24. The method of claim 23 , wherein the serine hydrolase enzyme is a monoacylglycerol lipase (MAGL) enzyme.

25. A method of modulating or inhibiting monoacylglycerol lipase (MAGL) in a subject in need thereof, comprising administering to the subject the compound of claim 1 .

26. A method of treating a disease, disorder, or condition which benefits from inhibition or modulation of monoacylglycerol lipase (MAGL) activity, comprising administering to a subject in need thereof the compound of claim 1 .

27. The method according to claim 26 , wherein the disease, disorder, or condition is selected from the group consisting of: a neurodegenerative disorder; primary tauopathies; neuropathy; withdrawal syndrome; metabolic disorder; burning feet syndrome; ischemia; nausea; vomiting or emesis; an eating disorder; a kidney disease; an eye disease; a lung disorder; osteoarthritis; osteoporosis; bipolar disease; depression; schizophrenia; sleeping sickness; cerebral palsy; cerebral edema; meningitis; cachexia; sleep apnea; De Vivo disease; spasticity; dystonia; progressive multifocal leukoencephalopathy; dyskinesia; tremor; hearing loss; insomnia; Tourette's syndrome; autism, bladder dysfunction, chronic motor or vocal tic disorder; trichotillomania; cognitive impairment; an inflammatory disorder; an autoimmune disease; a demyelinating disease; neuromyelitis optica; a disorder of the immune system; post-traumatic stress disorder (PTSD); acute stress disorder; panic disorder; substance-induced anxiety; obsessive-compulsive disorder (OCD); agoraphobia; a specific phobia; social phobia; anxiety disorder; attention deficit disorder (ADD); attention deficit hyperactivity disorder (ADHD); and Asperger's syndrome.

Assignments (1)

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 13, 2024

From: RABEA, SAFWAT MOHAMED; BOGUCKI, DAVID EARL; HU, KAIJI

To: APOGEE PHARMACEUTICALS, INC.

Reel/Frame 066451/0429 →

Continuity (2)

Provisional Application 63445124 · Feb 13, 2023

Related Publication 20240294514A1 · Sep 5, 2024

References Cited (79)

US 7700368B2 · Flockhar et al. · 2010 [cited by applicant]

US 10000450B2 · Kurimura · 2018 [cited by examiner]

US 10610520B2 · Ikeda et al. · 2020 [cited by applicant]

US 11147805B2 · Rashmi et al. · 2021 [cited by applicant]

US 11274101B2 · Kamata et al. · 2022 [cited by applicant]

US 20180264121A1 · Donaduzzi et al. · 2018 [cited by applicant]

US 20210188798A1 · Mueller · 2021 [cited by applicant]

WO 0232420A1 · 2002 [cited by applicant]

WO 2004026802A1 · 2004 [cited by applicant]

WO 2006116773A2 · 2006 [cited by applicant]

WO 2009052320A1 · 2009 [cited by applicant]

WO 2010056309A2 · 2010 [cited by applicant]

WO 2013098402A1 · 2013 [cited by applicant]

WO 2014100231A1 · 2014 [cited by applicant]

WO 2014127458A1 · 2014 [cited by applicant]

WO 2015003002A1 · 2015 [cited by applicant]

WO 2015065179A1 · 2015 [cited by applicant]

WO 2015179559A2 · 2015 [cited by applicant]

WO 2016014975A2 · 2016 [cited by applicant]

WO 2017021805A1 · 2017 [cited by applicant]

WO 2017170830A1 · 2017 [cited by applicant]

WO 2018053447A1 · 2018 [cited by applicant]

WO 2018093949A1 · 2018 [cited by applicant]

WO 2018109471A1 · 2018 [cited by applicant]

WO 2018134695A1 · 2018 [cited by applicant]

WO 2018134698A1 · 2018 [cited by applicant]

WO 2018217809A1 · 2018 [cited by applicant]

WO 2019046318A1 · 2019 [cited by applicant]

WO 2019046330A1 · 2019 [cited by applicant]

WO 201906579A1 · 2019 [cited by applicant]

WO 2019105915A1 · 2019 [cited by applicant]

WO 2019152917A1 · 2019 [cited by applicant]

WO 2019180185A1 · 2019 [cited by applicant]

WO 2019222266A1 · 2019 [cited by applicant]

WO 2020016710A1 · 2020 [cited by applicant]

WO 2020035424A1 · 2020 [cited by applicant]

WO 2020035425A1 · 2020 [cited by applicant]

WO 2020104494A1 · 2020 [cited by applicant]

WO 2020154683A1 · 2020 [cited by applicant]

Xu et al. Synthesis of Substituted Diarylmethylenepiperidines, a Novel Class of Anti-HIV agents(Bioorganic & Medicinal Chemistry, 10, p. 2807-2816) (Year: 2002). [cited by examiner]

Konstantinova et al. Chemoenzymatic Method of 1,2,4-Triazole Nucleoside Synthesis: Possibilities and Limitations (Russian Journal of Bioorganic Chemistry, 39:1, 53-71). (Year: 2013). [cited by examiner]

Teixeira et al. Inosine protects against impairment of memory induced by experimental model of Alzheimer disease, (Psychopharmacology, 237: 811-823). (Year: 2020). [cited by examiner]

Aubin, A., “Purification of Cannabidiol from Hemp Oil Using the Prep150 LC System.” Water Application Notes. http://www.waters.com/waters/webassets. 2015. [cited by applicant]

Bachovchin, D.A. et al. “The pharmacological landscape and therapeutic potential of serine hydrolases” Nat Rev. Drug Discov, 2012, vol. 11(1), p. 52-68. [cited by applicant]

Bedse et al. “Therapeutic endocannabinoid augmentation for mood and anxiety disorders: comparative profiling of FAAH, MAGL and dual inhibitors” Translational Psychiatry, 2018, vol. 8(1), p. 92. [cited by applicant]

Blessing et al., “Cannabidiol as a potential treatment for anxiety disorders”, Neurotherapeutics, 2015, vol. 12(4), p. 825-836. [cited by applicant]

Chou, T.C. et al. “CompuSyn for drug combinations: PC software and user's guide, A Computer Program for Quantitation of Synergism and Antagonism in Drug Combinations, and the Determination of IC50 and ED50 and LD50 Valu… [cited by applicant]

Consroe, P. et al. “Controlled clinical trial of cannabidiol in Huntington's disease” Pharmacol Biochem Behav, 1991, vol. 40(3), p. 701-708. [cited by applicant]

Cunha, J.M., et al. “Chronic administration of cannabidiol to healthy volunteers and epileptic patients” Pharmacology, 1980, vol. 21(3), p. 175-185. [cited by applicant]

Deng H, Li W. “Monoacylglycerol lipase inhibitors: modulators for lipid metabolism in cancer malignancy, neurological and metabolic disorders” Acta Pharm Sin B., 2020, vol. 10(4), p. 582-602. [cited by applicant]

Fu, J., et al. “Drug combination in vivo using combination index method: Taxotere and T607 against colon carcinoma HCT-116 xenograft tumor in nude mice” 2016, vol. 3(3), p. 15-30. [cited by applicant]

Guindon J, Hohmann AG, “CNS Neurol Disord Drug Targets” 2009, vol. 8(6), p. 403-421. [cited by applicant]

Huestis, M.A., “Human cannabinoid pharmacokinetics” Chem Biodivers, 2007, vol. 4(8), p. 1770-1804. [cited by applicant]

Karlsson, M., et al. “cDNA Cloning, Tissue Distribution, and Identification of the Catalytic Triad of Monoglyceride Lipase” Journal of Biological Chemistry, 1997, vol. 272(43), p. 27218-27223. [cited by applicant]

Kohnz R., et al. “Chemical approaches to therapeutically target the metabolism and signaling of the endocannabinoid 2-AG and eicosanoids” Chem Soc Rev., 2014. [cited by applicant]

Korhonen, J., et al. “Piperazine and piperidine carboxamides and carbamates as inhibitors of fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL)” Bioorganic & Medicinal Chemistry 22, 2014, p. 6694-6705. [cited by applicant]

Malamas, M.S., et al. “Design and sysnthesis of highly potent and specific ABHD6 inhibitors” ChemMedChem, 2023, vol. 18, e202100406 pp. 1-15. [cited by applicant]

Narayanaswami K et al. “Stability of [cited by applicant]

Pertwee, Handbook of Cannabis. 2014, Oxford: Oxford University Press. 784. [cited by applicant]

Remington, J.P. et al. “Remington's pharmaceutical sciences” 1990, Easton, PA.: Mack Pub. Co Chapters 89-92. [cited by applicant]

Remington, J.P. et al. “Remington's pharmaceutical sciences” 1990, Easton, PA.: Mack Pub. Co Chapters 82-88. [cited by applicant]

Remington, J.P. et al., “Remington's pharmaceutical sciences” 1990, Easton, PA.: Mack Pub. Co Chapters 75-81. [cited by applicant]

Repetto, M. et al. “Separation of cannabinoids” United Nations Office on Drugs and Crime (UNODC), 1976. [cited by applicant]

Sciolino et al., “Enhancement of endocannabinoid signaling with JZL 184, an inhibitor of the 2-arachidonoylglycerol hydrolyzing enzume monoacylglycerol lipase, produces anxiolytic effects under conditions of high enviro… [cited by applicant]

Smith, R.N. et al. “The decomposition of acidic and neutral cannabinoids in organic solvents” Journal of Pharmacy and Pharmacology, 1977, vol. 29(1), p. 286-290. [cited by applicant]

Stasiulewicz A, et al. “A Guide to Targeting the Endocannabinoid System in Drug Design” Int J Mol Sci., 2020, vol. 21 (8), p. 2778. [cited by applicant]

Tiwari P, et al. “Phytochemical screening and Extraction: A Review” Internationale Pharmaceutica Sciencia, 2011, vol. 1(1), p. 100-106. [cited by applicant]

Ulugöl A. “The endocannabinoid system as a potential therapeutic target for pain modulation” Balkan Med J. 2014, vol. 31(2), p. 115-20. doi: 10.5152/balkanmedj.2014.13103. Epub Jun. 1, 2014. PMID: 25207181; PMCID: PMC41… [cited by applicant]

Vuckovic, S. et al. “Cannabinoids and Pain: New insights from old molecules” Frontiers in Pharmacology, 2018, p. 1-19. [cited by applicant]

Zanfirescu A, et al. “Targeting Monoacylglycerol Lipase in Pursuit of Therapies for Neurological and Neurodegenerative Diseases. Molecules” 2021, vol. 26(18), p. 5668. doi: 10.3390/molecules26185668. PMID: 34577139; PMC… [cited by applicant]

Zuardi, A.W. “Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action” Braz J Psychiatr, 2008, vol. 30(3), p. 271-280. [cited by applicant]

Zuardi, A.W., et al. “Effects of ipsapirone and cannabidiol on human experimental anxiety” J Psychopharmacol, 1993, vol. 7(1 Suppl), p. 82-88. [cited by applicant]

Narayanaswami, K. et al., “Stability of [cited by applicant]

Pertwee, R. “Handbook of Cannabis” DOI: 10.1093/acprof:oso/9780199662685.011.0001, 2014. [cited by applicant]

Gennaro, A. R., “Remington's Pharmaceutical Sciences” Mack Publishing Company, 1990, Chapters 89-92, p. 1633-1712. [cited by applicant]

Gennaro, A. R., “Remington's Pharmaceutical Sciences” Mack Publishing Company, 1990, Chapters 82-88, p. 1513-1632. [cited by applicant]

Gennaro, A. R., “Remington's Pharmaceutical Sciences” Mack Publishing Company, 1990, Chapters 75-81, p. 1435-1512. [cited by applicant]

Repetto, M. et al. “Separation of cannabinoids” UNODC—Bulletin on Narcotics, 1976, vol. 4(007), p. 69-74. [cited by applicant]

Sciolino, N. R. et al., “Enhancement of endoannabinoid signaling with JZL 184, an inhibitor of the 2-arachidonoylgycerol hydrolyzing enzyme monoacylglycerol lipase, produces anxiolytic effects under conditions of high e… [cited by applicant]